THE WORLD’S FIRST tRNA PLATFORM COMPANY, DECIPHERING tRNA BIOLOGY AND PIONEERING tRNA THERAPEUTICS TO TREAT THOUSANDS OF DISEASES.

Alltrna is advancing universal tRNA medicines to restore disrupted protein production, regardless of gene targeted, for thousands of diseases with the same underlying genetic mutation.

tRNA’S UNIQUE ROLE IN PROTEIN CREATION IS KEY TO TREATING GENETIC DISEASES

Unlike other genetic medicines, engineered tRNAs can correct shared genetic mutations and restore disrupted protein production, no matter what protein is affected.

Learn more about tRNA biology

HARNESSING THE FULL POWER OF tRNA TO ACCELERATE AND SCALE GENETIC MEDICINES

tRNAs are programmable molecules with a diverse biology of sequences and chemical modifications. Alltrna’s platform turns tRNA’s sophisticated biology into programmable medicines that can accelerate and scale the creation of new genetic medicines.

See our tRNA platform

ONE OF MANY THERAPEUTIC APPLICATIONS FOR tRNA IS TREATING STOP CODON DISEASE

A number of genetic diseases are caused by nonsense mutations, where the code for an amino acid has been mutated into a ​premature termination or “stop” codon (PTC). This results in a truncated or absent protein that causes disease. Alltrna has engineered tRNAs that can specifically read PTCs and deliver the desired amino acid, thereby restoring the production of the full-length protein.

Learn about Stop Codon Disease

Life at Alltrna

We are driven by curiosity, courage, and passion to transform how drugs are developed for genetic diseases, because patients deserve better.

Explore what propels us forward
A man in a lab coat pouring a liquid into a beaker.

Recent news

View all news
Sort
Jan 6, 2025
Press Release
Alltrna Appoints Dr. Nerissa Kreher as Chief Medical Officer to Advance tRNA Medicines for Rare Diseases
Dec 9, 2024
Press Release
Alltrna Presents Preclinical Data Demonstrating Proof-of-Concept for First tRNA Development Candidate
May 24, 2024
Press Release
Alltrna Featured on Fast Company’s 2024 World Changing Ideas List for Advancing a Universal tRNA Medicine for Stop Codon Disease
Jul 17, 2024
Press Release
Alltrna Announces Updates to Its Board of Directors
May 16, 2024
Press Release
Alltrna Pioneers New Processes to Synthesize Chemically Modified tRNAs
May 7, 2024
Press Release
Alltrna Applies Machine Learning to Engineer tRNA Oligonucleotides with Significantly Improved Activity and Demonstrates In Vivo Readthrough of the Two Most Common Premature Termination Codons in Genetic Disease
Apr 22, 2024
Press Release
Alltrna Announces Presentations at ASGCT 27th Annual Meeting and TIDES USA 2024
Aug 15, 2023
Press Release
Alltrna Expands Leadership Team with Appointments of Chief Scientific Officer and Chief Technology Officer
Aug 9, 2023
Press Release
Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease
May 18, 2023
Press Release
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
Oct 17, 2022
Press Release
Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform
Aug 2, 2022
Press Release
Alltrna Expands Leadership Team with Appointment of Joanne Protano as Chief Financial Officer
Apr 11, 2022
Press Release
Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna
Mar 16, 2022
Video
Alltrna Announces Formation of Scientific Advisory Board with World-Leading RNA Experts
Feb 28, 2022
Press Release
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
Nov 9, 2021
Press Release
Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine
Dec 4, 2024
Podcast
[ExtERNAL]
In Vivo Citeline Commercial Podcast: Treating Rare Diseases With tRNA
Jul 25, 2024
Podcast
[ExtERNAL]
RARECast: A No-Nonsense Effort to Develop a Therapy that Works Across Genetic Diseases
Sep 13, 2024
Article
[ExtERNAL]
BioProcess International: Moving Beyond Protein Translation with tRNA
Sep 24, 2024
Article
[ExtERNAL]
Nucleic Acid Insights: Advancing Treatment of Genetic Diseases through Engineered tRNA Therapeutics
Sep 27, 2024
Podcast
[ExtERNAL]
Drug Target Review Podcast: Scaling Genetic Medicine with tRNA
Oct 18, 2024
Article
[ExtERNAL]
Drug Discovery World: How mRNA’s Tiny Cousin Could Treat Thousands of Rare Diseases
Jun 20, 2024
Podcast
[ExtERNAL]
The Genetics Podcast (Episode 139): Rare Disease Breakthroughs Using tRNA with Michelle Werner, CEO of Alltrna and CEO-Partner of Flagship Pioneering
Apr 29, 2024
Article
[ExtERNAL]
PharmaVoice: How a Biotech Exec is Leveraging Big Pharma Lessons to Advance tRNA
Apr 29, 2024
Press Release
[ExtERNAL]
Technology Networks: Tuning the Therapeutic Properties of tRNAs To Treat Rare Diseases
Feb 7, 2024
Press Release
[ExtERNAL]
Inside Precision Medicine: In Conversation with Michelle Werner
Dec 20, 2023
Article
[ExtERNAL]
Labiotech.eu: Wrapping up 2023: A Recap of Top Biotech Moments of This Year
Dec 19, 2023
Podcast
[ExtERNAL]
Raising Biotech Podcast (Episode 6): Alltrna and tRNA Therapeutics for Rare Genetic Diseases
Dec 14, 2023
Award
[ExtERNAL]
PM360 Magazine: Alltrna Named a 2023 Innovative Startup
Dec 4, 2023
Podcast
[ExtERNAL]
Alldus AI in Action Podcast (Episode 490): Theonie Anastassiadis & Stephen Eichhorn
Oct 6, 2023
Podcast
[ExtERNAL]
Beyond Biotech Podcast (Episode 66): Treating Rare Diseases with tRNA
Sep 25, 2023
Podcast
[ExtERNAL]
Biotech 2050 Podcast: Pioneering tRNA Therapeutics with Michelle Werner
Sep 19, 2023
Award
[ExtERNAL]
PharmaVoice 100 Stand-out Execs: Michelle Werner
Sep 14, 2023
Article
[ExtERNAL]
In Vivo: Exploring Alltrna’s Rare Disease Platform
Sep 6, 2023
Article
[ExtERNAL]
The Scientist: The Origins and Recent Promise of Nonsense Suppressor tRNAs
Aug 9, 2023
Article
[ExtERNAL]
MedCity News: Alltrna Unveils $109M to Make tRNA a Universal Therapy for Genetic Diseases
Aug 9, 2023
Article
[ExtERNAL]
Boston Business Journal: Flagship-backed RNA startup company raises $109M
Aug 9, 2023
Article
[ExtERNAL]
BioPharma Dive: Alltrna raises $109M for ‘transfer RNA’ drug vision
Aug 9, 2023
Article
[ExtERNAL]
MedCity News: Alltrna Unveils $109M to Make tRNA a Universal Therapy for Genetic Diseases
Aug 9, 2023
Article
[ExtERNAL]
Endpoints: Flagship startup Alltrna raises $109M for tRNA therapies that restore missing proteins
Aug 9, 2023
Article
[ExtERNAL]
BioCentury: Alltrna raises $109M for unified approach to stop codon diseases
Aug 9, 2023
Article
[ExtERNAL]
Fierce Biotech: Flagship's Alltrna collects $109M as it passes go to Stop Codon Disease
Aug 3, 2023
Video
[ExtERNAL]
VibeCast: Michelle C. Werner on Alltrna's tRNA Medicine for Stop Codon Disease | Episode 22
May 23, 2023
Article
[ExtERNAL]
GEN Edge: No-nonsense - Alltrna Touts tRNA Therapeutics to Treat Thousands of Diseases
Mar 1, 2023
Video
[ExtERNAL]
NYSE The Cure(ious): The Future of Health
Feb 22, 2023
Podcast
[ExtERNAL]
PharmaVoice Woman of the Week Podcast: Alltrna’s Michelle Werner
Nov 4, 2022
Award
[ExtERNAL]
C&EN: 10 Start-Ups to Watch for 2022
Jul 28, 2022
Article
[ExtERNAL]
Business Insider: Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs
Apr 11, 2022
Article
[ExtERNAL]
Endpoints Exclusive: Flagship snags another CEO-partner, on a personal mission, to lead its tRNA boat
Feb 23, 2022
Podcast
[ExtERNAL]
Biotech 2050: Episode 91 Alltrna
Nov 15, 2021
Article
[ExtERNAL]
Barron’s: A New Start-Up Explores Another Genome for Medicines
Nov 9, 2021
Article
[ExtERNAL]
Boston Business Journal: With $50M, Flagship Pioneering makes another big RNA play: Alltrna
Nov 9, 2021
Article
[ExtERNAL]
BioPharma Dive: Moderna founder unveils new drug company focused on a different kind of RNA
Nov 9, 2021
Article
[ExtERNAL]
BioSpace: Flagship Debuts Alltrna to Unlock the Mysteries of tRNA
Nov 9, 2021
Article
[ExtERNAL]
C&EN: Alltrna launches with $50 million for tRNA therapies
Nov 9, 2021
Article
[ExtERNAL]
Boston Globe: Flagship Pioneering unveils another RNA startup, backing it with $50 million
Nov 9, 2021
Article
[ExtERNAL]
Endpoints: A new Flagship startup looks to crack tRNA biology in search for completely new class of therapeutics
Nov 9, 2021
Article
[ExtERNAL]
Fierce Biotech: Flagship unveils its next RNA bet with $50M for Alltrna to explore thousands of genetic diseases using transfer RNA
Nov 9, 2021
Article
[ExtERNAL]
MedCity News: Flagship’s next genetic meds startup has $50M for transfer at a critical protein stop